Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination strategies[1], with the FDA fast-tracking multiple targeted therapies designed to ...

A new AI tool is revolutionizing cancer treatment decisions by analyzing tissue images to predict tumor aggressiveness. This ...

The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...

Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...

Shares of Adagene Inc. (NASDAQ:ADAG) jumped more than 16% in pre-market trading on Tuesday after the biotech company said the ...

The results of the study could improve immunotherapy treatment for patients with colorectal and other barrier-tissue cancers.

Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of ...

In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the ...

In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor.

Oniria Therapeutics SL, Vall d’Hebron Institute of Oncology (VHIO) and Institut Català d’Investigació Química (ICIQ) have partnered to advance ONR-001 for the treatment of colorectal cancer and to ...

Older Americans with metastatic breast, colorectal, lung, or prostate cancer are spending an increasing amount of time in the ...